Navigation Links
Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
Date:7/15/2008

SOMERSET, N.J., July 15 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that it has entered into a distribution agreement with Megapharm Ltd., a leading pharmaceutical company in Israel, for the commercialization of ONCONASE(R) (ranpirnase) in Israel. ONCONASE, the company's lead drug candidate, recently completed an international confirmatory Phase IIIb clinical trial for unresectable malignant mesothelioma (UMM).

Under the agreement, Alfacell has granted Megapharm exclusive rights in the defined territory for the marketing, sales and distribution of ONCONASE. Alfacell will receive 50% of all sales in the territory. In addition, Alfacell will manufacture and supply the product to Megapharm, while Megapharm will be responsible for all activities and costs related to regulatory filings and commercial activities in the territory.

Miron Drucker, CEO and founder of Megapharm, said, "Having been interested observers in the development of ONCONASE, a first-in-class anti-cancer agent, we are proud to include this unique product in our oncology portfolio. We believe that ONCONASE will prove to be a promising new treatment option for patients suffering from mesothelioma."

"We are very pleased to add Megapharm to our growing list of important regional partners for ONCONASE," said Kuslima Shogen, chief executive officer of Alfacell. "Megapharm's role as a leader in biotechnology marketing in Israel provides Alfacell with an ideal partner to maximize the potential of ONCONASE in this region. We look forward to a successful collaboration with Megapharm."

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) techn
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
5. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
6. Alfacells ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
7. Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... , Oct. 2, 2014  AxelaCare Health Solutions, ... services, announced today that it has acquired Advanced Care, ... intravenous therapy provider.  Terms of the transaction were not ... AxelaCare,s intravenous solutions pharmacies to 18 nationwide and expands ... New York - New Jersey ...
(Date:10/2/2014)... Intarcia Therapeutics, Inc. today announced successful top-line results ... for ITCA 650 (exenatide, delivered continuously once or twice ... trial, FREEDOM-1, was a placebo-controlled, double-blind phase 3 clinical ... 650 in patients with type 2 diabetes against placebo. ... to placebo for both 40 mcg and 60 mcg ...
(Date:10/1/2014)... NOTTINGHAM, England , Oct. 1, 2014  Columbia ... that its subsidiary, Molecular Profiles Ltd., is set to ... annual CPhI/ICSE Worldwide event in Paris ... the rapid development of both standard and complex drug ... which incorporates the company,s existing formulation and analytical development ...
Breaking Medicine Technology:AxelaCare Health Solutions Acquires Advanced Care of New York 2AxelaCare Health Solutions Acquires Advanced Care of New York 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 2Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 3
... ... treatment, Dr. Carl Giordano - based in Morristown - among first surgeons ... ... N.J., July 29 Leading New Jersey orthopedic,surgeon Dr. Carl Giordano, of Morristown-based Atlantic ...
... Md., July 29 Micromet, Inc.,(Nasdaq: MITI ... the treatment of cancer, inflammation and autoimmune,diseases, today ... and audio,webcast on Thursday, August 7, 2008, at ... to discuss its second quarter 2008 financial,results. Micromet ...
Cached Medicine Technology:NJ-Based Surgeon Helps Pioneer Dramatic Advance in Treating Damaged Discs 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 3
(Date:10/2/2014)... October 02, 2014 There has been ... new demand has resulted in an increase in the ... of different services at very affordable prices. A leading ... many professional SEO hosting companies and announced that InMotion ... who want to buy hosting products. , InMotion ( ...
(Date:10/2/2014)... PA (PRWEB) October 02, 2014 ... of the 2014 BIG Awards for Business program. ... and organizations with a proprietary judging process scored ... around the globe. , “The winners this year ... Russ Fordyce, Managing Director of the Business Intelligence ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, ... a neurotic personality style and prolonged stress may have ... suggests. Tracking 800 women over nearly four decades, ... jealous and moody -- which they defined as neurotic ... of developing Alzheimer,s compared to women scoring lowest in ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 ... raise your risk for high blood pressure, a new study ... lived within 109 yards of a busy road had a ... women living at least half a mile away, researchers report. ... of our physical environment on our health and well-being," said ...
(Date:10/2/2014)... Dennis Thompson HealthDay ... Forty-two states and the District of Columbia now have a ... respiratory illness that has been infecting children since the ... with the virus have died in recent weeks, but it,s ... played in those deaths, officials said. Health officials are ...
Breaking Medicine News(10 mins):Health News:Innovation Dominant Theme among 2014 Big Awards for Business Winners and Finalists 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3
... A new study that is to appear in the May ... American Cancer Society says that weight training// improves the quality ... breast cancer. A bi-weekly exercise regimen for six months improves ... ,In the initial days after therapy for breast cancer, ...
... need to perform more physical activities or exercise to keep themselves ... people age, there is a decline in the exercise or work ... led by Wayne C. Levy at the University of Washington in ... aging cardiovascular system being less able to send oxygen to working ...
... danced to the taste buds of many a watering mouth. Yet, ... somber//. Cast away from star hotels and foreign trips, to land ... say the least! ,Taking a trip down memory lane, ... own sons of the soil-amongst people in small towns and villages, ...
... Defence Minister Pranab Mukherjee has urged the military doctors to ... services, in the rapidly changing global scenario in order to ... are the most potent form of delivering healthcare both to ... disasters, the minister said while opening the 16th Asia-Pacific Military ...
... used gene technology to breed animals that produce fats. The ... key gene inserted in them. // ,The result was ... produce compounds useful for the heart. ,According to researcher Dr ... could use these animals as a model to see what happens ...
... planned to open a laboratory to test for the avian ... laboratory may come up in the Keoladeo Ghana bird sanctuary ... Ghana was chosen because thousands of birds from various countries ... in the region. ,The Bharatpur sanctuary is ...
Cached Medicine News:Health News:Pranab Mukherjee Urged Military Doctors To Remain On The Cutting Edge 2
Single channel module for Finnpipette Biocontrol - Universal handle sold separately...
... The Research pro Electronic Pipette is ideal ... laboratory. Its easy-to-follow display, ergonomically-placed operating buttons, ... dispensing, reverse pipetting and diluting make this ... simple functions of a manual pipette without ...
An automatic system for determining erythrocyte sedimentation rate (ESR) in EDTA tube and using cell counter racks....
MiniVes has been specifically designed for the doctors office and near patient testing and it uses normally freshly collected blood that shall be mixed manually by 15 complete inversion of the tube a...
Medicine Products: